Skip links

GSS EU Science Funding Gateway

Pandemic preparedness and response: Understanding vaccine induced-immunity

Summary

Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.

Programme Name

Horizon Europe (2021-2027)

Programme Description

Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.

Programme Details

Call

Pandemic preparedness and response: Understanding vaccine induced-immunity

Detailed Call Description

Proposals should aim to improve the global vaccine research and development pipeline for emerging and re-emerging viral infections, and to strengthen the current leading role of the EU in vaccine development, and therefore contributing to the work of the European Health Emergency Preparedness and Response Authority (HERA).

Proposals should study vaccine-induced immunity in the general population and vulnerable groups. Proposals should look both at the magnitude and breadth of initial immune responses and the duration of immunity after vaccination with different vaccine types (mRNA, vector, inactivated, subunit, attenuated,…). Proposals should assess how sex (e.g. male vs female, pre- vs postmenopausal), age (childhood vs adolescent vs elderly) and/or lifestyle (e.g. obesity, drug addiction, diet, sport) affect the immune response. Proposals may also examine genetic and other molecular factors that may influence immune response in humans. Proposals should pursue a multi-omics approach in order to foster a deep understanding of vaccine induced immunity. Proposals should identify correlates of protection that can be used to develop vaccines against viruses meeting the criteria for pathogens with high pandemic potential as identified by HERA. Proposals should also assess how pre-existing conditions or chronic infections influence the immune response.

Financing percentage by EU or other bodies / Level of Subsidy or Loan

100%

Contribution per project: between €7,00 and €8,00 million

Eligibility For Participation Notes

In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.

If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).

  • The scientific and clinical communities
Programme Category
EU Competitive Programmes
Total Budget
€20,00 million
Thematic Categories
  • Health
  • Research, Technological Development and Innovation
Eligibility for Participation
  • Associations
  • Other Beneficiaries
  • Private Bodies
  • Researchers/Research Centers/Institutions
Call Opening Date
12/01/2023
Call Closing Date
13/04/2023
National Contact Point(s)

Research and Innovation Foundation

29a Andrea Michalakopoulou, 1075 Nicosia
P.O.Box 23422, 1683 Nicosia
Telephone: +357 22205000
Email Address: support@research.org.cy
Website: https://www.research.org.cy/en/

Contact Persons:
George Christou

Scientific Officer
Email: gchristou@research.org.cy

Ioannis Theodorou
Scientific Officer
Telephone: +357 22 205 038
Contact Email: itheodorou@research.org.cy

(Publish Date: 09/02/2023-for internal use only)

EU Contact Point

European Commission, Directorate-General for Research and Innovation

https://ec.europa.eu/info/departments/research-and-innovation_en#contact

Website
Funding&Tenders HE Main Work Programme 2023–2024 – Health p.82
This website uses cookies to improve your web experience.
Home
Account
Cart
Search
Explore
Drag